• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Toolbar - View Selection
 
Items 1 of 1
ALX-430-161 Revised 21-Jul-08 New product
Flavopiridol
Add to Clipboard
SYNONYMS Alvocidib
(-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one
PRODUCT LINE Cell Cycle
PRODUCT CATEGORY CDK & Cyclin Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-430-161-M005   5 mg 60.00 USD Add To Cart
ALX-430-161-M025   25 mg 240.00 USD Add To Cart
Product Specification
FORMULA: C21H20ClNO5
MW: 401.8
CAS NUMBER: 146426-40-6
MERCK INDEX: 14: 4094
SOURCE/HOST: Synthetic.
PURITY: ≥97% (HPLC)
APPEARANCE: Yellow powder.
SOLUBILITY: Soluble in chloroform; slightly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: HARMFUL.
IDENTITY: Identity determined by 1H-NMR.

Product Description

Potent inhibitor of cyclin-dependent kinases  (CDKs). Induces apoptosis in certain tumor cells. Interacts with multidrug resistance protein 1 (MRP1).

Product Specific Literature References
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase: W.F. Jr. De Azevedo, et al.; PNAS 93, 2735 (1996) Abstract; Full Text
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells: B.A. Carlson, et al.; Cancer Res. 56, 2973 (1996) Abstract; Full Text
Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells: K.C. Bible & S.H. Kaufmann; Cancer Res. 56, 4856 (1996) Abstract; Full Text
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells: M. Drees, et al.; Clin. Cancer Res. 3, 273 (1997) Abstract; Full Text
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines: A. König, et al.; Blood 90, 4307 (1997) Abstract; Full Text
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts: F. Arguello, et al.; Blood 91, 2482 (1998) Abstract; Full Text
Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells: S. Brüsselbach, et al.; Int. J. Cancer 77, 146 (1998) Abstract
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53: J.C. Byrd, et al.; Blood 92, 3804 (1998) Abstract; Full Text
Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein: J.B. Schnier, et al.; FEBS Lett. 454, 100 (1999) Abstract
Potent interaction of flavopiridol with MRP1: J.H. Hooijberg, et al.; Br. J. Cancer 81, 269 (1999) Abstract
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials: A.M. Senderowicz; Invest. New Drugs 17, 313 (1999), (Review) Abstract
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia: S. Kitada, et al.; Blood 96, 393 (2000) Abstract; Full Text
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells: U. Raju, et al.; Cancer Res. 63, 3263 (2003) Abstract; Full Text
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics: A. Pumrery, et al.; Curr. Pharm. Des. 12, 1949 (2006) Abstract
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL: T.E. Fandy, et al.; Cancer Chemother. Pharmacol. 60, 313 (2007) Abstract
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors: C. Sekine, et al.; J. Immunol. 180, 1954 (2008) Abstract
Further Categories Containing This Product:
Antitumor Agents (Apoptosis Inducers)MDR Other Products
 
 

Your items will be kept only for the duration of your visit.